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Abstract
The length of the CAG repeat tract is the major determinant of age of onset (AO) of 
Huntington’s Disease (HD) However, there remains a significant variance in AO when the 
expanded repeat size is ruled out. The search for genetic modifiers has revealed various 
candidate loci; however, many reports have been contradictory. The N-methyl-d-aspartate 
receptors (NMDAR) have been proposed as an important putative modifier. We aimed to 
determine whether polymorphisms in NMDAR-coding genes have an effect on the AO. 
We analyzed the association between GRIN1 (rs6293), GRIN2A (rs1969060), and GRIN2B 
(rs1806201, rs890) polymorphisms and AO of Turkish HD patients. According to our find-
ings, expanded CAG repeat size explains 41.8% of the variance in AO. Upon classification 
of genotypes into CAG repeat length intervals, rs6293 can be considered as an AO modifier 
for Turkish HD patients with 50 or higher CAG repeats. In addition to that, we found a sig-
nificant association of this polymorphism to HD, with the GG genotype constituting a risk 
factor. Candidate genetic modifiers should be tested in different populations since their 
effects may exist only in groups of specific ethnic origins. Defining such modifiers will 
help in complete understanding of HD pathogenesis and in designing therapeutic targets.
Keywords: Huntington’s disease, polyglutamine repeats, age of onset, NMDA 
receptors, GRIN
1. Introduction
Huntington’s disease (HD) is a progressive neurodegenerative disorder of the central ner-
vous system characterized by involuntary movements, cognitive impairment, and emotional 
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disturbances [1]. The prevalence of the disease is about 1/10,000 among individuals of 
European descent [2]. The disease follows an autosomal dominant pattern of inheritance 
and is associated with an expanded block of CAG repeats in exon 1 of the IT15 gene [3]. 
The CAG repeats are translated into a polyglutamine (polyQ) tract near the N-terminus 
of the huntingtin (htt) protein, which acquires a deleterious gain of function in the mutant 
protein. This ubiquitously expressed protein is shown to be essential for development 
[4–6]. Analysis of htt-interactors revealed that htt may function in intracellular traffick-
ing, neurotransmission, retrograde transport, cytoskeletal function, and transcriptional 
regulation [7–9].
Four CAG repeat size intervals associated with varying disease risks were defined. The alleles 
with up to 35 repeats are considered normal. However, repeats in the range of 29–35 have 
been shown to exhibit meiotic instability. Rare alleles with 36–39 repeats are in the reduced 
penetrance range, since some people with repeats in this range develop HD and others do 
not. On the other hand, alleles with 40 or more CAG repeats definitely cause HD in a normal 
life span [10].
HD usually strikes in the third to fourth decade of life and gradually worsens over a course 
of 10–20 years until death. The patients may differ in the type and severity of their symp-
toms, age of onset (AO), and disease duration. The number of CAG repeats in the IT-15 
gene is the most important factor determining the AO. There is a significant inverse cor-
relation between the AO and the CAG repeat length [11, 12]. However, the number of the 
CAG repeats does not allow an accurate prediction of AO, only 30–70% of the variance in 
AO can be explained by the repeat size alone [13–20]. The AO varies significantly among 
individuals with the same CAG size, and even monozygotic HD twins may show pheno-
typic discordance for the disease [21, 22]. This has led to a search for genetic modifiers and 
environmental factors that influence the AO. Diverse modifier candidate loci have been sug-
gested to be associated with AO in HD such as GRIN, TP53, hCAD, UCHL1, BDNF, ASK1, 
and MTHFR [14, 17, 23–32]. However, many reports from different research groups have 
been contradictory.
The NMDA glutamate receptors (GRIN: glutamate receptor, ionotropic, N-methyl-d-aspartate) 
have been proposed as an important putative modifier, since glutamate (Glu) mediates fast 
excitatory neurotransmission in the brain. Neurodegeneration in HD is highly selective for 
striatal GABA-ergic medium-sized spiny neurons (MSNs) that project to the substantia nigra 
(SN) and globus pallidus [33]. The underlying mechanisms are poorly understood; neverthe-
less, models of neurodegeneration suggested excitotoxicity, oxidative stress, and impaired 
energy metabolism as relevant to selective pathogenesis in HD [34]. Excitotoxicity may play 
a major role in the pathogenesis of HD, because Glu is the principal excitatory neurotrans-
mitter in the mammalian central nervous system (CNS) and its excessive extracellular lev-
els for prolonged periods can lead to excitotoxicity [35]. Glutamate activates two classes of 
receptors in neurons: metabotropic glutamate receptors (mGluRs) coupled to G-proteins 
and ionotropic glutamate receptors (iGluRs) controlling ion channels. The most intensely 
studied subclass related to excitotoxicity is the NMDARs, since intrastriatal injections of an 
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NMDA receptor agonist, quinolinic acid, produce lesions similar to the HD neuropathology, 
selectively affecting the striatal projection neurons [36–38]. Upon activation, the NMDAR 
channel becomes permeable to Ca2+ and Na+, and NMDAR overactivity results in excessive 
Ca2+ loads. As homeostatic Ca2+ mechanisms are overwhelmed, a number of intracellular 
mechanisms are induced, leading to cellular damage by degradative enzymes [39].
Individual NMDARs are multimeric assemblies of subunits and the combination of NR1 
with different NR2 subunits alters the characteristics of the NMDAR ion channel. NR2A-
containing receptors are generally expressed at synapses and they are associated with 
developmental regulation and synaptic maturation; NR2B-containing receptors seem to be 
predominant at extrasynaptic sites. Therefore, the expression patterns of NR2A- and NR2B-
containing NMDARs may have differential roles in mediating excitotoxic neuronal death [40]. 
The striatum, the most vulnerable region of the brain in HD, appears to express higher levels 
of NR2B subunit relative to other NR2 subunits when compared to other brain regions [41]. 
Studies with postmortem HD brains showing losses of striatal NMDAR-binding sites indicate 
that MSNs with higher levels of NMDAR expression are at particular risk [42]. A number of 
studies have demonstrated enhancement of the NMDAR currents in several transgenic HD 
mouse models [42–46]. Furthermore, an NR2B-selective hypothesis of mutant htt-mediated 
enhancement has been suggested [47]. Mutant protein caused an increase in the responses of 
NMDARs composed of NR1/NR2B, whereas NR1/NR2A NMDARs were not differentially 
affected by normal or mutant htt [48]. YAC72 MSNs were shown to be more susceptible to 
NMDA-induced toxicity than wild-type MSNs, and additionally, the enhancement of apop-
tosis by mutant htt in YAC46 and YAC72 MSNs was proportional to the length of the polyQ 
repeat, arguing a relationship of altered NMDAR signaling and mutant htt polyQ length 
[49]. These findings strongly support the hypothesis of excitatory amino acid-mediated and 
particularly NMDAR-induced cell death in HD. Therefore, NMDAR activity and/or subunit 
composition may have effects not only in the downstream effector pathways but also on the 
AO in HD patients.
Recent analysis by Arning and coworkers [17] indicated that variations of the NR2A and 
NR2B genes could explain the variance in AO especially in HD patients with CAG repeat 
lengths in the high 30s to the low 40s. In a replication study with Venezuelan kindreds, no 
evidence was obtained for the association of NR2B single nucleotide polymorphisms (SNPs); 
however, they found evidence for association of an NR2A SNP [24]. In an expanded HD 
cohort, Arning and coworkers confirmed the results of the previous study [14]. In addition to 
that, gender stratification of patients revealed differences in the variability in AO attributable 
to the CAG repeat number and highly significant differences in the AO association with the 
NR2A and NR2B variations [14].
In this study, we aimed to investigate the modifier effects of GRIN1, GRIN2A, and GRIN2B 
SNPs (rs6293, rs1969060, rs1806201, rs1042339, and rs890) on AO in Turkish HD patients. 
Defining genetic modifiers of AO in different ethnic populations is of great importance, since 
they may provide further clues to explain disease pathology and to construct neuroprotective 
strategies.
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2. Materials and methods
2.1. Subjects and patient diagnosis
DNA samples of 102 unrelated HD patients (46 men and 56 women) were included in the 
study. Clinical examination and determination of motor AO was performed by experienced 
neurologists. The CAG repeat sizes of the patients were ascertained by polymerase chain reac-
tion (PCR) using primers 5′FAM-HD3: 5′-GGCGGTGGCGGCTGTTGCTGCTGCTGCTGC-3′ 
and P3F: 5′-TCTGCTTTTACCTGCGGCC-3′, followed by capillary electrophoresis and frag-
ment analysis using PeakScanner v.1.0 software (Iontek, Turkey). One hundred and two 
healthy age- and sex-matched controls were also genotyped for comparison. The control 
subjects and their families were free of neurological disorders. All subjects provided written 
informed consent for genotyping. The experiments performed comply with the current laws 
of Turkey, and the study was approved by the Halic University Human Researches Ethics 
Committee.
2.2. SNP genotyping
All studied SNPs were checked from the single nucleotide polymorphism database 
(dbSNP). Genotyping of GRIN1, GRIN2A, and GRIN2B polymorphisms was performed by 
PCR-RFLP analysis [17]. PCR was carried out in a final volume of 25 μl with 50 ng of DNA, 
2.0 mM Mg2+, 0.8mM dNTP, 10 pmol of each primer, and 1 U Taq polymerase. The cycling 
conditions for each polymorphism included an initial denaturation step at 94°C for 5 min, 
followed by 35 cycles of denaturation at 94°C for 1 min, annealing at 48–60°C for 1 min, 
extension at 72°C for 1 min, and a final extension at 72°C for 10 min (Table 1). PCR products 
were digested with 2 U of the appropriate restriction enzymes under optimal reaction con-
ditions (Table 1) for 2 h and visualized on 2% agarose gels stained with ethidium bromide. 
Genotypes were confirmed with Sanger sequencing (Iontek, Istanbul) sequence analysis of 
25 randomly selected samples.
2.3. Statistical analysis
Hardy-Weinberg (HW) test statistics was computed for each SNP. In order to compare allele 
frequencies between cases and controls, a standard case-control association analysis was 
performed using PLINK (http://pngu.mgh.harvard.edu/~purcell/plink/). The dependence 
of AO on the expanded CAG repeat size was assessed by linear regression. The effects 
of the GRIN1, GRIN2A, and GRIN2B genotypes on AO were analyzed by multiple linear 
regression approach. The CAG repeat number and the respective genotypes were used as 
independent variables, and AO was used as the dependent variable. The CAG repeat size 
was considered as numerical, modifying genotypes were considered as nominal variables 
and they were encoded as “0, 1, 2.” The odds ratios (OR) and independent-samples T-tests 
for genotypes were computed for the association of genotypes with AO. All the statistical 
analyses were performed with Statistical Package for Social Sciences (SPSS) version 17.0 for 
Windows.
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Gene/polymorphism Primer sequences 5′ → 3′ Annealing temperature Restriction enzyme Allele sizes (bp)
GRIN1/rs6293 NR1F: CGTTCTTGCCGTTGATGA 
NR1R: GTAAGAGCCAGCAACGGAG
60.3°C MspI G allele: 138 + 113 + 59 + 114 
A allele: 251 +173
GRIN2A/rs19690600 2Ars1969060F: 
GGTTTTAAGATTTGTGCCAGG 
2Ars1969060R: 
CTTAGACCGAGTTGGCAACA
60.3°C DdeI T allele: 280 + 45  
C allele: 166 + 114 + 45
GRIN2B/rs1806201 2Brs1806201F: 
AGACTATTCGCTTCATGC 
2Brs1806201R: 
GTGTGTTGTTCATGGCTG
48.3°C PstI C allele: 210  
T allele: 194 + 16
GRIN2B/rs890 2Brs890F: GCTGTCAGCCATTCCTGTT 
2Brs890R: 
CATGAATTTAGCCAGAGCCTC
57.1°C PsuI G allele: 283  
T allele: 194 + 89
GRIN2B/rs1042339 2Brs1042339F: 
GACCACAAGCGCTACTTCAG 
2Brs1042339R: 
TGTCATACAGGTTGCCTGCT
53.7°C PsyI G allele: 263 + 146  
A allele: 409
Table 1. PCR and RFLP conditions of the studied polymorphisms.
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3. Results
The patients were given the clinical diagnosis of HD upon neurological examination and 
thereafter clinical diagnosis was ascertained with molecular test results. The clinical symp-
toms of the patients included choreic movements, intellectual and cognitive impairment, 
dementia, and depression.
In the studied patient cohort, 22 different mutant alleles carrying 39–75 CAGs were deter-
mined; the most frequent range was between 42 and 47 repeats. The disease AO ranges 
between 16 and 80 years, the mean AO (±SD) being 40.75 (±12.97) years (Table 2). There are 
wide variations in ages of onset for a given CAG repeat length in our patient population, 
which is a strong indicative of other genetic or environmental modifiers.
CAG repeat length AO range (years) AO mean (years)
39 69 69
40 42–73 55.25
41 20–75 43.71
42 35–60 50.27
43 40–80 52.25
44 28–48 41.58
45 24–57 38.88
46 37–52 42
47 30–62 40.23
48 26–36 32.8
49 28–45 37.6
50 27 27
51 25–39 30
52 25–36 31.17
53 25–32 28.5
54 23–35 29
55 23 23
56 19–23 21
58 22 22
59 16 16
67 22 22
75 16 16
Table 2. CAG repeat sizes of the patients and corresponding AO ranges and means.
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Allele and genotype frequencies were deduced in HD cases and controls according to HW 
principles and evaluated with chi-squared goodness-of-fit test. In patients and controls, allele 
and genotype frequencies were found in HW equilibrium. All genotypes except the 3501A 
variant (rs1042339) in the GRIN2B gene were observed in the patient and control groups; 
therefore, this polymorphism was excluded from the analyses. Genotype frequencies of stud-
ied SNPs among HD patients and controls are summarized in Table 3.
Linear regression analysis has shown that 41.8% of the variance in AO could be attributed 
to the expanded CAG repeat size in the studied population (R2 = 0.418, p < 0.0001). In order 
to evaluate the contributions of the studied SNPs to the AO, R2-values were determined for 
each SNP in conjunction with the effect of the expanded CAG repeat size. The R2-values of 
the SNP genotypes and the CAG repeats alone were compared to determine the change in R2 
(ΔR2) (Table 4). In our HD patient cohort, the studied genotype variations at GRIN1, GRIN2A, 
and GRIN2B did not show any significant increase in the R2-values; therefore, they do not 
contribute to the variation in AO. Gender stratification of patients did not reveal any differ-
ences in the variability in AO attributable to the CAG repeat number and putative modifier 
polymorphisms. Upon classification of the CAG repeat sizes into four groups (40–45, >45, 
40–50, and >50 CAGs) to expand the findings, a significant regression model was obtained 
only for GRIN1 rs6293 (p = 0.016) in the >50 CAGs group. The other groups did not reveal 
any significant regression models. The power of the analysis reached 99.9%, and at least 42 
Gene polymorphism GRIN1 rs6293 GRIN2A 
rs1969060
GRIN2B 
rs1806201
GRIN2B rs890 GRIN2B 
rs1042339
Genotypes AA CC CC GG AA
AG CT CT GT AG
GG TT TT TT GG
Patients % 42.16 1.96 44.12 26.47 0
48.04 30.39 48.04 46.08 0
9.8 67.65 7.84 27.45 100
n 43 2 45 27 0
49 31 49 47 0
10 69 8 28 102
Controls % 52.94 6.86 41.18 24.51 0
43.14 27.45 49.02 54.90 0
3.92 65.69 9.80 20.59 100
n 54 7 42 25 0
44 28 50 56 0
4 67 10 21 102
Table 3. Genotype frequencies among patients and control subjects.
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patients were essential to detect a significant effect with GRIN2A rs1969060, analysis of the 
other SNPs required 44 patients. With a sample population of 102 patients, we are beyond the 
minimum number of required patients.
Although there is no significant finding, the multiple linear regression data for GRIN2A 
rs1969060 could be regarded as a trend (p = 0.132) (Table 4). Moreover, HD patients with 
genotype CC had higher mean AO (50 years) than that of remaining HD patients (40 and 
57 years) (Figure 1). The risk estimation analysis have shown that, compared to combined 
genotypes CT and TT, genotype CC can be regarded as protective (OR = 0.271). However, the 
observed differences in AO did not prove to be significant according to the results of indepen-
dent samples t-test (p = 0.31).
R2 ΔR2 % additional variance p-value
HD CAG 0.418 – – 0.000
HD CAG + GRIN1 
(rs6293)
0.418 0.000 0 0.917
HD CAG + GRIN2A 
(rs1969060)
0.431 0.013 2.22 0.132
HD CAG + GRIN2B 
(rs1806201)
0.422 0.004 0.007 0.406
HD CAG + GRIN2B 
(rs890)
0.419 0.001 0.002 0.695
Table 4. Multiple linear regression analysis of the SNPs.
Figure 1. The AO distribution among rs1969060 genotypes is represented as box plots. For each genotype, the median 
AO is represented as a black bar, the quartile is shown as a solid box, and the range is indicated by margins.
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In addition to that, although GRIN2B rs180620 polymorphism did not reveal an important 
regression model, HD patients with genotype TT had lower mean AO (35 years) than those 
having the remaining genotypes (41.18 years). However, upon independent samples t-test, 
this difference was not found to be significant (p = 0.23), either.
The result of simple associations test (Table 5) has shown that the distribution of GRIN1 
rs6293 GG genotype was significantly different in patient and control groups (p = 0.01478). 
Upon this finding, risk analysis was performed and the OR value was calculated to be 2663, 
indicating that the GG genotype could be a risk factor in HD.
4. Discussion
It has been well established that the AO is inversely correlated with the number of CAG 
repeats in the mutant HD allele. On the other hand, the negative correlation between AO and 
repeat size is stronger for higher repeat numbers (earlier AO) and weaker for lower repeat 
numbers (later AO). This indicates that although the CAG size is the major determinant of 
onset age particularly in juvenile patients, factors other than the repeat size should contribute 
to onset in later ages [50]. Previous studies have shown that the CAG repeat number alone 
explained 30–70% of the variance in AO [13–15, 17–20]. In various studies, many gene poly-
morphisms were defined as possible candidates for explaining the remaining variance. The 
genes encoding htt-interacting proteins or proteins that are found to be involved in disease 
pathology were regarded as the major candidate modifiers. In this study, we aimed to evalu-
ate the hypothesis that polymorphisms in GRIN1, GRIN2A, and GRIN2B genes that code for 
NMDAR subunits may contribute to explain the variability in AO in Turkish HD patients.
According to our findings, expanded CAG repeat size explains 41.8% of the variance in AO, 
which is in accordance with the results from other populations. However, when the entire 
observed CAG repeat sizes are considered, the remaining variance could not be attributed to 
any of the studied SNPs. Classification of SNP genotypes into four CAG repeat length inter-
vals did not reveal any important findings either, except GRIN1 rs6293 in the >50 CAG repeats 
group (p = 0.016). As a result, rs6293 SNP can be considered as an AO modifier for Turkish HD 
patients with 50 or higher CAG repeats in their IT15 gene. Also, the results of the association 
test indicated a significant association of this SNP to HD (p = 0.015) and further risk analysis 
revealed that the GG genotype constitutes a risk factor (OR = 2.663).
SNP A1 F_A F_U A2 CHISQ P OR L95 U95
rs6293 G 0.348 0.2321 A 5.942 0.01478 1.766 1.115 2.796
rs1806201 T 0.3137 0.3333 C 0.171 0.6792 0.9143 0.5979 1.398
rs890 T 0.5049 0.4804 G 0.2452 0.6205 1.103 0.7481 1.626
rs1969060 C 0.1716 0.2059 T 0.7844 0.3758 0.7988 0.4856 1.314
Table 5. Association analysis of SNPs using PLINK (A1: minor allele, A2: major allele, F_A: Frequency of minor allele 
in patients (F_U: frequency of minor allele in controls, CHISQ: chi-squared test, L95 and U95: lower and upper bounds 
of 95% confidence interval).
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Prior to this study, the effects of the SNPs in NMDAR-coding genes in determining AO in HD 
were investigated in the German population [14, 23] and a replication study was performed 
with Venezuelan kindreds [24]. In the Arning's work, German HD patients having 41–45 CAG 
repeats in their mutant HD alleles were intentionally selected. In this cohort, the contribution 
of the expanded CAG repeat size to the AO was calculated to be 30.8%, while variations in 
the GRIN2A (rs1969060) and GRIN2B (rs1806201) genes accounted for 4.5 and 12.3% of the 
remaining variance, respectively. In addition to that, GRIN2B rs1806201 (C2664T) variation 
resulted in a difference of 2.8 years between the genotypes and patients having TT geno-
type that had earlier AO than those having other genotypes [17]. In our sample population, 
although GRIN2B rs180620 polymorphism did not reveal an important regression model, TT 
genotype did show lower mean AO (35 years) than the remaining genotypes (41.18 years). 
Arning and coworkers expanded their findings with 8 additional SNPs and 83 additional HD 
patients with repeat sizes varying between 39 and 61 [14]. In that study, when GRIN2A and 
GRIN2B genotype variations were considered together in the multiple regression analysis, 
7.2% of the additional variance could be explained. Furthermore, the classification of patients 
according to sex revealed a significant difference and 5.6% additional variance was attrib-
uted to C2664T genotype variations in women. Female HD patients with the CC genotype 
tended to have delayed onset compared to the other two genotypes. In our study, we could 
not deduce any significant results out of gender stratification. In the Venezuelan kindreds, 
GRIN2B 1806201 association could not be replicated; however, GRIN2A rs1969060 SNP was 
found to be associated with AO, with a very slight increase in R2 (ΔR2 = 0.003). They found 
3.9 year difference in the mean age of onset between the CT and TT genotype classes. They 
found that TT genotype was protective. On the contrary, in our population HD patients with 
CC genotype have about 10 years higher mean AO than that of the remaining patients, which 
may imply toward a protection effect. However, due to very few numbers of patients with the 
CC genotype, this result does not reach statistical significance. As mentioned by Andresen et 
al. [24], heterozygosity at this polymorphic locus varies greatly by geographical variation and 
the results should be evaluated carefully. The C allele frequency was established to be 17% in 
European, 52–56% in Asian and African, and 24% in Venezuelan populations. The data from 
our population are in accordance with that of the European population (17.2% in HD patients 
and 20.6% in control subjects).
Apart from our study, GRIN1 rs6293 was investigated only with the German HD patients 
with repeat numbers 41–45 [17], which demonstrated a trend for explaining the variance in 
AO (p = 0.055). On the contrary, we established GRIN1 rs6293 as an AO modifier for Turkish 
HD patients with 50 or higher CAG repeats in their IT15 gene.
In summary, the effects of the genetic variations in the GRIN1, GRIN2A, and GRIN2B genes 
have been investigated in a very few numbers of populations until now and the results could 
not be replicated. The major reason for this discrepancy could be that the effect of these poly-
morphisms on AO may exist only in groups of similar genetic backgrounds or of specific 
ethnic origin. Therefore, further investigations involving HD patients of various ethnic popu-
lations with a wide range of CAG repeat sizes are required to clarify the issue. However, these 
negative findings are far from ruling out NMDA receptors as an important biological effector 
in the pathophysiology of HD. Ample evidence suggests an important role for NMDARs in 
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selective vulnerability of MSNs and neuronal cell death in HD. While there is evidence that 
NMDARs play an important role in the pathogenesis of HD, their exact roles and the modi-
fying effects of the polymorphism remain to be further investigated. It is clear that numer-
ous supplemental studies are needed to establish a confirmed association of GRIN genes as 
genetic modifiers of AO in HD.
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